REGN5093-M114 (METxMET Antibody-Drug Conjugate)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for REGN5093-M114 (METxMET Antibody-Drug Conjugate), covering 2025-11-03 to 2025-11-03. Get the full timeline:
Most recent: Clinical Trial Update: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer [Phase 1]